Ann Coloproctol Search


Ann Coloproctol > Volume 35(2); 2019 > Article
Kim, Yeom, Kwak, Lee, Ju, Kim, and Kim: Clinical Outcomes of Patients With Locally Advanced Rectal Cancer With Persistent Circumferential Resection Margin Invasion After Preoperative Chemoradiotherapy



Treatment after failure of circumferential resection margin (CRM) conversion after preoperative chemoradiotherapy (pCRT) for locally advanced rectal cancer (LARC) has not been evaluated well. We conducted a single‐center, retrospective analysis to fill this information gap.


From 2008 to 2016, we included 112 patients who had predictive CRM involvement on baseline magnetic resonance imaging (MRI) and who underwent surgery following pCRT for LARC. Baseline and posttreatment radiologic and clinical factors were analyzed.


Of 493 patients with LARC, 112 had CRM involvement by baseline MRI (mrCRM). In 40 patients (35.7%), mrCRM involvement was converted as negative posttreatment CRM (ymrCRM−). Multivariate analysis showed the risk factors for persistent CRM involvement (ymrCRM+) after pCRT were extramural venous invasion (mrEMVI+) (P = 0.030) and lower tumor location (P = 0.007). In addition, persistent CRM involvement after pCRT was an independent risk factor for predicting pathologic CRM involvement. The Cox proportional hazard model showed baseline positive mrEMVI remained significant for disease-free survival (DFS) (P < 0.001). On posttreatment MRI, abdominoperineal resection (P = 0.031), intersphincteric resection (P = 0.006), and persistent CRM involvement (P = 0.001) remained significant for local recurrence-free survival. With regard to DFS, persistent CRM involvement (P = 0.048) and positive EMVI on posttreatment MRI (ymrEMVI) (P = 0.014) were significant. In the patient subgroup with persistent CRM involvement, 5-year DFS in patients with mrEMVI and ymrEMVI was 29.8% and 21.2%, respectively.


Patients who fail to convert to negative CRM have extremely poor oncologic outcomes. Lower tumor height and negative mrEMVI status were good responders to ymrCRM conversion. Our results suggest that these patients require a more intensive treatment modality.


After introduction of total mesorectal excision (TME) and preoperative chemoradiotherapy (pCRT), the local recurrence rate after surgery for locally advanced rectal cancer (LARC) decreases significantly [1]. Over the last decade, continuous efforts have been made to use tailored treatment strategies for these patients. Although there are many efforts to preserve the rectum and to improve the functional outcome of LARC treatment [2, 3], knowledge of tumors that require more extensive surgical and/or oncologic treatment is limited.
In this regard, the most recent National Comprehensive Cancer Network (NCCN) guidelines recommend an additional 12 to 16 weeks of chemotherapy, if persistent circumferential resection margin (CRM) involvement or residual bulky tumor is revealed on restaging magnetic resonance imaging (MRI) after completion of pCRT. However, this strategy has not been supported by firm evidence and was only assessed in a small study with 45 patients [4]. Furthermore, few studies have evaluated the oncological outcome of patients with failed CRM conversion after pCRT for LARC, and the number of patients included was limited (38–88 patients) [5, 6].
In this study, we report the results for oncologic outcomes of patients who had CRM involvement on pretreatment MRI. This study aimed to identify the predictors of persistent CRM involvement despite the use of current standard long-course pCRT and pathologic CRM. Furthermore, we also assessed the prognostic relevance, as judged by local recurrence-free survival (LRFS) and disease-free survival (DFS), of posttreatment MRI parameters in patients with persistent CRM involvement.


Prospectively collected data from 493 patients with rectal cancer who underwent surgery after pCRT at our tertiary care academic center between January 2009 and June 2016 were reviewed retrospectively. The study was approved by the Institutional Review Board of Chonnam National University Hwasun Hospital (TMP-2019-85), which waived the requirement for informed consent in this retrospective study. Of 493 patients, 112 had CRM involvement based on pretreatment MRI. Patients with negative CRM involvement (n = 365) and metastatic disease (n = 5), those who refused to undergo surgery (n = 2), those without baseline MRI (n = 8), and those who underwent local excision (n = 1) were excluded (Fig. 1). Pretreatment clinical evaluation included physical examination, rigid sigmoidoscopy, colonoscopy, abdominopelvic computed tomography (CT), rectal MRI, chest CT, and measurement of serum carcinoembryonic antigen (CEA).
All patients treated with pCRT underwent posttreatment MRI 4–6 weeks after completion of pCRT. Details of the pCRT have been previously described [7]. Radiotherapy consisted of 4,040–4,500 cGy in 25–28 fractions delivered to the primary tumor and pelvic lymph node by using a 4-field box technique. During the first and fifth weeks of radiotherapy, chemotherapy, consisting of 5-fluorouracil (425 mg/m²/day) and leucovorin (20 mg/m²/day), was administered intravenously. Adjuvant chemotherapy was initiated 4–6 weeks postoperatively in patients who received preoperative or postoperative CRT. MRI was assessed by 2 radiologists and reviewed at a multidisciplinary team meeting. The distal edge of the rectal tumor was measured from the anal verge on the basis of rigid sigmoidoscopy, and tumors within 15 cm were included in the study. Low rectal cancer was defined as having low (<5 cm), mid (≤5 and <10 cm), and upper borders (≥10 cm) from the anal verge. In addition, tumor size, lymph node involvement, CRM, and vascular invasion were measured using electronic calipers on a PACS system. Baseline MRI CRM (mrCRM) involvement was defined if the tumor distance to the mesorectal fascia was <1 mm on MRI. Tumor regression grade by MRI (mrTRG) was defined as previously reported [8]. In this study, the 5-score system was simplified to a binary score (1/2 vs. 3/4/5).
Surgical options included high ligation of the inferior mesenteric artery, TME, or extended TME (TME with en bloc resection of the adjacent involved organ). The interval between preoperative CRT and surgery was 6–8 weeks. The patients underwent standardized follow-up at 3-month intervals for 2 years and at 6-month intervals for the next 3 years. Local recurrence was defined as any recurrent disease in the pelvic cavity, including bowel anastomosis. Distant metastasis was defined as disease outside the pelvis.
The χ2 test or Fisher exact test was used to analyze the significance of categorical variables, and the Student t-test was used for continuous variables. Univariate logistic regression analysis was used to identify the predictors of ymrCRM and pathologic CRM (ypCRM) in the pre- and posttreatment variables, respectively. Variables that were significant at P < 0.10 in the univariate analysis were considered in a backward stepwise multivariate logistic regression model. The Kaplan-Meier method was used to establish the effects of each variable, and log-rank tests were used to compare survival curves. Multivariate survival analyses were performed using Cox regression models with calculation of hazard ratios (HRs) and 95% confidence intervals (CIs). These analyses were performed separately on the pretreatment variables (i.e., mrT, mrN, and mrEMVI), posttreatment variables (i.e., ymrT, ymrN, ymrCRM, ymrEMVI, and ymrTRG), and pathologic variables (i.e., ypT, ypN, ypCRM, and ypTRG). P < 0.05 was considered statistically significant. Statistical analysis was performed using R ver. 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria).


The median follow-up period of our cohort of 112 patients was 40.6 months (range, 4.2–107.6 months). Of the 112 patients considered to have potential mrCRM involvement before pCRT, 40 (35.7%) had mrCRM conversion. Table 1 shows the demographic characteristics and association between persistent CRM involvement and variables defined before pCRT. Univariate analysis showed baseline MRT (P = 0.020), EMVI (P < 0.001), and tumor location (P = 0.055) were associated with persistent CRM involvement. Multivariate analysis using logistic regression showed that lower tumor location (odds ratio [OR], 3.927; 95% CI, 1.492–11.182, P = 0.007) and positive EMVI on baseline MRI (OR, 3.319; 95% CI, 1.146–10.149; P = 0.030) were significant predictive factors for persistent CRM involvement.
Table 2 summarizes the results of uni- and multivariate analyses of posttreatment MR-based variables based on pathologic CRM involvement. Univariate analysis showed posttreatment CEA (P = 0.038), posttreatment MR T (ymr) (P = 0.005), ymr N (P = 0.021), ymr EMVI (P = 0.002), persistent CRM involvement (P < 0.001), surgery type (P = 0.018), and ymr TRG (P = 0.036) were significantly associated with pathologic CRM involvement. Multivariate analysis showed persistent CRM involvement on post-treatment MRI (OR, 7.030; 95% CI, 1.497–52.515; P = 0.025), intersphincteric resection (ISR; OR, 5.748; 95% CI, 1.765–21.801; P = 0.006), and abdominopelvic resection (APR; OR, 6.164; 95% CI, 219–35.071; P = 0.031) were significant predictive factors of pathologic CRM involvement.
During the follow-up period, the local recurrence was 20 of 72 (27.8%) and 4 of 40 (10.0%) in the persistent CRM involvement and converted CRM groups, respectively. Distant metastasis was found in 42 of 72 patients (58.9%) and 12 of 40 patients (30.0%) in the persistent CRM involvement and converted CRM groups, respectively. Uni- (Table 3) and multivariate (Table 4) analyses were performed to address the prognostic significance of persistent CRM status for LRFS and DFS, as well as other parameters. Of pretreatment variables, baseline positive mrEMVI remained significant for DFS (HR, 6.007; 95% CI, 1.846–19.546; P < 0.001). For the posttreatment variables, APR (P < 0.001) and ISR (P < 0.012) remained significant for LRFS. In addition, persistent CRM involvement (HR, 4.380; 95% CI, 1.469–13.058; P = 0.008) showed significance. With regard to DFS, persistent CRM involvement (HR, 1.832; 95% CI, 1.020–3.702; P = 0.048) and positive ymrEMVI (HR, 2.111; 95% CI, 1.164–3.826; P = 0.014) were significant. Finally, of the pathologic parameters, pathologic CRM involvement was identified as significant not only for LRFS (HR, 9.580; 95% CI, 3.458–26.535; P < 0.001), but also for DFS (HR, 2.349; 95% CI, 1.352-4.068; P = 0.002). ypN was only significant for DFS (HR, 2.292; 95% CI, 1.290–4.067; P = 0.004). Given the prognostic importance of persistent CRM involvement and positive EMVI, the Kaplan-Meier survival curves based on ymrCRM and ymrEMVI status are shown in Fig. 2. A subgroup analysis of the persistent CRM involvement group showed that the 5-year LRFS and DFS were significantly poor among patients with positive baseline MR EMVI compared to those who did not have a positive baseline MR EMVI (LRFS [67.9% vs. 95.6%, P = 0.200], DFS [36.8% vs. 87.0%, P = 0.002]). Similarly, the oncologic outcomes were also significantly poor among patients with positive ymrEMVI (LRFS [57.7% vs. 86.2%, P = 0.003], DFS [27.1% vs. 62.8%, P < 0.001]) (Fig. 3).


In this study, the overall CRM conversion rate was 35.7% in patients with CRM invasion before pCRT. The oncologic outcomes of these patients who did not convert after pCRT were very poor, and positive EMVI on both pre- or posttreatment MRI could further prognostic information on these patients.
Measurement of CRM involvement in rectal cancer is crucial and well-known as the most powerful prognostic factor for successful surgery [9]. Many studies support the value of CRM involvement not only for LRFS, but also for DFS and overall survival. These results clarified that CRM involvement after pCRT is also important even in patients without pCRT [9]. Although several studies proposed alternative clinical parameters (i.e., mrTRG, tumor volume based on MRI), many studies demonstrate the superiority of CRM [10, 11].
The present study evaluates the significance of CRM in LARC requiring more extensive surgery (i.e., beyond the TME plane) after standard long-course pCRT. The results suggest that pathologic CRM remains the most powerful independent prognostic factor for both LRFS and DFS. Multivariate analysis showed persistent CRM involvement of the posttreatment variable was an independent predictor for pathologic CRM involvement. This result supports the current NCCN guidelines, which regard ymrCRM as a decision tool for deferring surgery and additional chemotherapy. Actually, only 2 of 40 patients (5%) with converted CRM showed pathologic CRM involvement after surgery. By contrast, in patients showing persistent CRM involvement, ypCRM positive rate was 36%, and 4 (5.5%) R2 resections and 3 perforations (4.1%) were observed. Similarly, Simpson et al. [6] reported that 7 of their 18 patients (38.9%) with persistent CRM involvement on posttreatment MRI had positive histological margins. In this regard, we can infer that the specificity of posttreatment CRM is low in contrast to its high sensitivity. Therefore, we suggest that surgical exploration should not be abandoned, unless resection is strongly contraindicated, before we obtain firm evidence of a well-performed clinical study. However, surgical planning should include a wider safe margin when surgical resection is attempted in this clinical situation. In our study, ISR and APR were significant predictors of not only pathologic CRM involvement but also poor LRFS. This result is concurrent with that of our previous study that suggested a more radical modification of the standard APR in the treatment of patients with persistent CRM involvement [12].
Furthermore, we identified the factors for prediction of persistent CRM involvement. Tumor location (≥5 cm) and presence of mrEMVI were predictors of persistent CRM involvement after preoperative CRT. This finding is consistent with the previous literature, which reports that negative baseline MRI EMVI (OR, 2.94; P = 0.007), tumor location ≤5 cm (OR, 1.96; P = 0.02), and mrEMVI status change (positive to negative) following pCRT (OR, 3.09; P < 0.001) were the only predictors for response rather than baseline tumor size and tumor stage [13, 14]. In terms of tumor location, the reason for the good tumor response after pCRT in lower rectal tumors is unclear. A plausible explanation is that relatively fixed anatomical structure in the lower rectum could enable more accurate radiotherapy.
EMVI was defined as tumor cell invasion into the surrounding vessels. Concurrent with tumor location, positive mrEMVI (present in 78.5% of patients) was significantly associated with low CRM conversion rates. This result suggests that this subgroup of patients is resistant to current long-course pCRT and could benefit most from induction chemotherapy [15, 16] or additional systemic salvage treatment [4].
In this study, as stated above, unacceptable high ypCRM involvement rate and poor LRFS in patients who did not achieve CRM conversion were shown. In addition to the unsatisfactory local control, poor DFS must also be considered in this group of patients. This result suggests that failure of CRM conversion can be a significant predictor of distant metastasis and local recurrence. Previous studies have shown that positive EMVI is significantly associated with poor 5-year OS, DFS, and LRFS [17]. Our result also showed similar results; positive mrEMVI was associated with a 6-fold increase in the risk of distant metastasis and reduction of 5-year DFS from 87% to 36.8% compared with patients without mrEMVI. Strikingly, this poor prognosis is more pronounced in patients with persistent CRM involvement, as shown in Fig. 3. In a subgroup of patients with persistent CRM involvement, the 5-year DFS in patients with mrEMVI and ymrEMVI was 29.8% and 21.2%, respectively, which is similar to the oncologic outcome for resectable stage IV colorectal cancer [18-20].
This study has potential limitations because of its retrospective nature and relatively small sample size. For example, more details on MR scoring (i.e., mrTRG, meEMVI, both systems use 5-scoring systems) systems were not used and analyzed. However, many strengths also exist, such as largely homogeneous management for a relatively short period of time, high rate of treatment compliance, and to the best of our knowledge, the largest number of patients analyzed.
In conclusion, our study suggests that the current treatment of pCRT and surgery be reconsidered for reaching agreement with NCCN guidelines. Posttreatment mrCRM and EMVI status can be used for decision-making for surgical treatment or salvage systemic treatment, initial baseline EMVI status is a candidate indicator for intensive induction chemotherapy.


No potential conflict of interest relevant to this article was reported.

Fig. 1.
Flow diagram. pCRT, preoperative chemoradiotherapy; mrCRM, circumferential resection margin based on pretreatment magnetic resonance imaging; ypCRM, pathologic circumferential resection margin.
Fig. 2.
Survival analysis in entire patients. Local recurrence-free survival (LRFS) (A) and Distant metastasis-free survival (DFS) (B) between positive ymrCRM group and negative ymrCRM group. LRFS (C) and DFS (D) between positive ymrEMVI group and negative ymrEMVI group. ymrCRM, circumferential resection margin evaluated after preoperative chemoradiotherapy (pCRT); ymrEMVI, extramural venous invasion evaluated after pCRT; F/U, follow-up.
Fig. 3.
Survival analysis in persistent circumferential resection margin positive group after preoperative chemoradiotherapy. Local recurrencefree survival (LRFS) according to mrEMVI state (A) and ymrEMVI state (B). Disease-free survival (DFS) according to mrEMVI state (C) and ymrEMVI state (D). mrEMVI, extramural venous invasion evaluated on pretreatment magnetic resonance imaging; ymrEMVI, extramural venous invasion evaluated after preoperative chemoradiotherapy.
Table 1.
Univariable and multivariable analysis of persistent circumferential resection margin (CRM) invasion on magnetic resonence imaging after preoperative chemoradiotherapy
Variable Univariate analysis
P-value Multivariate analysis
Persistent CRM (n = 72) Converted CRM (n = 40) OR 95% CI
Age (yr) 64.0 ± 11.0 65.0 ± 10.5 0.617
Sex 1.000
 Male 51 (70.8) 29 (72.5)
 Female 21 (29.2) 11 (27.5)
Body mass index (kg/m²) 22.6 ± 3.1 22.9 ± 2.6 0.602
Hemoglobin (g/dL) 12.7 ± 2.3 12.7 ± 2.4 0.925
Tumor location 0.055 0.007
 Low 17 (23.6) 18 (45.0) 1.000 -
 Mid/upper 55 (76.4) 22 (55.0) 3.927 1.492–11.182
Tumor size (cm) 0.977
 ≤5 29 (40.3) 17 (42.5)
 >5 43 (59.7) 23 (57.5)
CEA at diagnosis (ng/mL) 0.122
 ≤5 26 (36.1) 21 (52.5)
 >5 46 (63.9) 19 (47.5)
mrT category 0.020 0.268
 2/3 47 (65.3) 35 (87.5) 1.000 -
 4 25 (34.7) 5 (12.5) 1.936 0.628–6.771
mrN category 0.458
 0 6 (8.3) 7 (17.5)
 1 21 (29.2) 10 (25.0)
 2 45 (62.5) 23 (57.5)
mrEMVI <0.001 0.030
 No 8 (11.1) 16 (40.0) 1.000 -
 Yes 64 (88.9) 24 (60.0) 3.319 1.146–10.149
Differentiation 0.421
 Well 38 (52.8) 25 (62.5)
 Moderately 31 (43.1) 15 (37.5)
 Poorly 3 (4.2) 0 (0)
Pathologic CRM 0.436
 Involved 26 (36.1) 2 (5.0)
 Not involved 46 (63.9) 38 (95.0)

Values are presented as mean ± standard deviation or number (%).

CEA, carcinoembryonic antigen; EMVI, extramural venous invasion; OR, odds ratio; CI, confidence interval.

Table 2.
Univariable and multivariable analysis of pathologic circumferential resection margin (CRM) invasion after surgery
Variable Univariate analysis
P-value Multivariate analysis
Pathologic CRM not involved (n = 84) Pathologic CRM involved (n = 28) OR 95% CI
Age (yr) 65.1 ± 10.6 62.1 ± 11.2 0.222
Sex 1.000
 Male 60 (71.4) 20 (71.4)
 Female 24 (28.6) 8 (28.6)
Body mass index (kg/m²) 22.8 ± 2.8 22.4 ± 3.2 0.536
Hemoglobin (g/dL) 12.9 ± 2.2 12.7 ± 2.5 0.127
Tumor location 0.178
 Low 24 (28.6) 11 (39.3)
 Mid/upper 60 (71.4) 17 (60.7)
Tumor size at after CRT (cm) 0.512
 ≤5 47 (56.0) 13 (46.4)
 >5 37 (44.0) 15 (53.6)
CEA after CRT (ng/mL) 0.038 0.134
 ≤5 24 (28.6) 2 (7.1) 1.000 -
 >5 60 (71.4) 26 (92.9) 3.557 0.795–25.669
ymrT category 0.005 0.164
 0–2 77 (91.7) 19 (67.9) 1.000 -
 3–4 7 (8.3) 9 (32.1) 2.859 0.662–13.314
ymrN category 0.021 0.469
 Negative 44 (52.4) 7 (25.0) 1.000 -
 positive 40 (47.6) 21 (75.0) 1.539 0.480–5.097
ymr EMVI 0.002 0.524
 No 56 (66.7) 9 (32.1) 1.000 -
 Yes 28 (33.3) 19 (67.9) 1.501 0.429–5.373
Differentiation 0.381
 Well 50 (59.5) 13 (46.4)
 Moderately 32 (38.1) 14 (50.0)
 Poorly 2 (2.4) 1 (3.6)
ymr CRM <0.001 0.025
 Converted 38 (45.2) 2 (7.1) 1.000 -
 Not converted 46 (54.8) 26 (92.9) 7.030 1.497–52.515
Surgery type 0.018
 LAR 46 (54.8) 7 (25.0) 1.000 -
 ISR 30 (35.7) 15 (53.6) 5.748 1.765–21.801 0.006
 APR 7 (8.3) 6 (21.4) 6.164 1.219–35.071 0.031
mrTRG 0.036
 0–2 20 (23.8) 2 (7.1) 1.000 - 0.711
 3/4 64 (76.2) 26 (92.9) 1.557 0.190–33.111

Values are presented as mean ± standard deviation or number (%).

CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; EMVI, extramural venous invasion; OR, odds ratio; CI, confidence interval; LAR, low anterior resection; ISR, intersphincteric resection; APR, abdominoperineal resection; mrTRG, magnetic resonance imaging tumor regression grade.

Table 3.
Univariate analysis for local recurrence-free survival (LRFS) and disease-free survival (DFS)
Variable LRFS
HR (95% CI) P-value HR (95% CI) P-value
Before CRT
 Age (yr)
  ≤65 vs. >65 1.008 (0.453–2.246) 0.983 1.071 (0.628–1.827) 0.799
  Male vs. female 1.862 (0.635–5.455) 0.226 1.263 (0.709–2.246) 0.433
 Body mass index (kg/m²)
  ≤25 vs. >25 4.770 (0.644–35.355) 0.090 1.176 (0.574–2.408) 0.651
 Tumor location
  Low vs. mid/upper 2.595 (1.159–5.806) 0.023 1.379 (0.787–2.418) 0.269
 Tumor size (cm)
  >5 vs. ≤5 2.361 (1.056–5.277) 0.039 1.554 (0.893–2.704) 0.126
 CEA at diagnosis (ng/mL)
  >5 vs. ≤5 1.831 (0.819–4.089) 0.140 1.499 (0.878–2.558) 0.139
 mrT category
  4 vs. 2/3 3.620 (1.585–8.253) 0.003 2.207 (–1.238–3.933) 0.010
 mrN category
  N+ vs. N0 3.584 (0.484–26.543) 0.125 2.595 (0.809–8.318) 0.063
  Yes vs. no 9.003 (1.211–66.901 0.002 7.026 (2.184–22.593) 0.001
  WD vs. MD/PD 1.228 (0.550–2.743) 0.617 1.481 (0.867–2.525) 0.151
After CRT
 Tumor size at after CRT (cm)
  >5 vs. ≤5 3.952 (1.727–9.047) <0.001 1.554 (0.893–2.704) 0.126
 CEA after CRT (ng/mL)
  >5 vs. ≤5 2.749 (1.173–6.446) 0.027 2.359 (1.065–5.223) 0.019
 ymrT category
  4 vs. 2/3 5.323 (2.270–12.483) <0.001 2.576 (1.339–4.958) 0.009
 ymrN category
  N+ vs. N0 2.603 (1.078–6.284) 0.025 1.510 (0.880–2.590) 0.140
  Yes vs. No 3.456 (1.476–8.091) 0.003 2.665 (1.543–4.603) <0.001
  Not converted vs. converted 3.471 (1.184–10.170) 0.010 2.537 (1.332–4.833) 0.002
  0–2 vs. 3/4 6.321 (1.010–46.757) 0.015 2.720 (1.083–6.831) 0.014
Pathologic variable
 Surgery type
  SSS vs. SPS 2.716 (1.071–6.884) 0.054 1.538 (0.723–3.271) 0.287
 Lymphovascular invasion
  Yes vs. no 2.397 (0.949–6.056) 0.088 1.435 (0.700–2.941) 0.343
 Perineural invasion
  Yes vs. no 3.032 (1.345–6.835) 0.007 1.510 (0.880–2.590) 0.140
 Pathologic CRM
  Involved vs. not involved 10.325 (4.258–25.033) <0.001 3.472 (2.020–5.965) <0.001
 Pathologic T
  3/4 vs. 0–2 2.864 (0.672–12.210) 0.100 3.437 (1.239–9.534) 0.004
 Pathologic N
  Yes vs. No 2.608 (1.114–6.103) 0.022 2.175 (1.225–4.844) 0.015
 Distal margin (cm)
  <1 vs. ≥1 0.864 (0.257–2.902) 0.810 1.037 (0.467–2.301) 0.928
 Pathologic TRG
  0–2 vs. 3/4 1.516 (0.676–3.399) 0.314 1.001 (0.577–1.735) 0.998

CRM, circumferential resection margin; CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; EMVI, extramural venous invasion; HR, hazard ratio; CI, confidence interval; mrTRG, magnetic resonance imaging tumor regression grade; LAR, low anterior resection; ISR, intersphincteric resection; APR, abdominoperineal resection; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; TRG, tumor regression grade.

Table 4.
Multivariate analysis for local recurrence-free survival (LRFS) and disease-free survival (DFS)
Variable LRFS
HR (95% CI) P-value HR (95% CI) P-value
Before CRT
 Tumor location
  Low vs. mid/upper 3.205 (1.251–8.209) 0.015
 Tumor size (cm)
  >5 vs. ≤5 4.224 (1.771–10.078) 0.001
 mrT category
  4 vs. 2/3 4.762 (1.843–12.302) 0.001
  Yes vs. no 6.007 (1.846–19.546) <0.001
After CRT
 ymrT category
  LAR vs. ISR 4.303 (5.010–59.211) 0.012
  LAR vs. APR 17.223 (1.782–10.019) <0.001
  Not converted vs. converted 4.380 (1.469–13.058) 0.008 1.832 (1.020–3.702) 0.048
  Yes vs. no 2.111 (1.164–3.826) 0.014
Pathologic variables
 Pathologic N
  Yes vs. no 2.292 (1.290–4.067) 0.004
 Pathologic CRM
  Involved vs. not involved 9.580 (3.458–26.535) <0.001 2.349 (1.352–4.068) 0.002

CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; EMVI, extramural venous invasion; HR, hazard ratio; CI, confidence interval; mrTRG, magnetic resonance imaging tumor regression grade; LAR, low anterior resection; ISR, intersphincteric resection; APR, abdominoperineal resection.


1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–40.
crossref pmid
2. Wiltink LM, Chen TY, Nout RA, Kranenbarg EM, Fiocco M, Laurberg S, et al. Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer 2014;50:2390–8.
crossref pmid
3. Habr-Gama A, Sabbaga J, Gama-Rodrigues J, São Julião GP, Proscurshim I, Bailão Aguilar P, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 2013;56:1109–17.
crossref pmid
4. Sclafani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, et al. Systemic Chemotherapy as salvage treatment for locally advanced rectal cancer patients who fail to respond to standard neoadjuvant chemoradiotherapy. Oncologist 2017;22:728–36.
crossref pmid pmc
5. Lee NK, Kim CY, Park YJ, Yang DS, Yoon WS, Kim SH, et al. Clinical implication of negative conversion of predicted circumferential resection margin status after preoperative chemoradiotherapy for locally advanced rectal cancer. Eur J Radiol 2014;83:245–9.
crossref pmid
6. Simpson GS, Eardley N, McNicol F, Healey P, Hughes M, Rooney PS. Circumferential resection margin (CRM) positivity after MRI assessment and adjuvant treatment in 189 patients undergoing rectal cancer resection. Int J Colorectal Dis 2014;29:585–90.
crossref pmid
7. Kim CH, Lee SY, Kim HR, Kim YJ. Pathologic stage following preoperative chemoradiotherapy underestimates the risk of developing distant metastasis in rectal cancer: a comparison to staging without preoperative chemoradiotherapy. J Surg Oncol 2016;113:692–9.
crossref pmid
8. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011;29:3753–60.
crossref pmid
9. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008;26:303–12.
crossref pmid
10. Glynne-Jones R, Mawdsley S, Pearce T, Buyse M. Alternative clinical end points in rectal cancer--are we getting closer? Ann Oncol 2006;17:1239–48.
crossref pmid pdf
11. Glynne-Jones R, Anyamene N. Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer? Int J Radiat Oncol Biol Phys 2006;66:319–20.
crossref pmid
12. Kim CH, Lee SY, Kim HR, Kim YJ. Factors associated with oncologic outcomes following abdominoperineal or intersphincteric resection in patients treated with preoperative chemoradiotherapy: a propensity score analysis. Medicine (Baltimore) 2015;94:e2060.
crossref pmid pmc
13. Yu SK, Tait D, Chau I, Brown G. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy? Int J Radiat Oncol Biol Phys 2013;87:505–11.
crossref pmid
14. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007;109:1750–5.
crossref pmid
15. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010;11:241–8.
crossref pmid
16. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012;30:1620–7.
crossref pmid
17. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008;95:229–36.
crossref pmid
18. Kim CH, Huh JW, Kim HR, Kim YJ. Indeterminate pulmonary nodules in colorectal cancer: follow-up guidelines based on a risk predictive model. Ann Surg 2015;261:1145–52.
crossref pmid
19. Kim CH, Huh JW, Kim HJ, Lim SW, Song SY, Kim HR, et al. Factors influencing oncological outcomes in patients who develop pulmonary metastases after curative resection of colorectal cancer. Dis Colon Rectum 2012;55:459–64.
crossref pmid
20. Bae SU, Han YD, Cho MS, Hur H, Min BS, Baik SH, et al. Oncologic outcomes of colon cancer patients with extraregional lymph node metastasis: comparison of isolated paraaortic lymph node metastasis with resectable liver metastasis. Ann Surg Oncol 2016;23:1562–8.
crossref pmid pdf


Browse all articles >

Editorial Office
Room 526, Suseo Hyundai Venture-vill, 10 Bamgogae-ro 1-gil, Gangnam-gu, Seoul 06349, Korea
Tel: +82-2-2040-7737    Fax: +82-2-2040-7735    E-mail:                

Copyright © 2019 by Korean Society of Coloproctology. All rights reserved.

Developed in M2community

Close layer
prev next